WHO Interim Guidelines for the Treatment of Gambiense Human African Trypanosomiasis


Book Description

Human African trypanosomiasis (HAT), or sleeping sickness, is a parasitic infection that is almost invariably fatal unless treated. It is a neglected tropical disease that occurs in sub-Saharan Africa. The incidence of the disease is declining in response to intensive surveillance and control in endemic areas. As a result, HAT is among the neglected tropical diseases targeted by the World Health Organization (WHO) for elimination. WHO maintains exhaustive records of all declared cases; in 2018, a historically low number of cases (less than 1000) was reported. The remarkable progress in the control of gambiense HAT has relied on case-finding and curative treatment, a strategy that interrupts transmission by depleting the reservoir of parasites in humans. This has been combined occasionally with vector control activities. The subject of these guidelines, therefore, is of utmost importance for the continuation of progress to eliminate HAT. The recent approval of a new medicine (fexinidazole) for the treatment of gambiense HAT has opened new possibilities for the management of cases and thus warrants the new WHO recommendations contained herein. While studies of fexinidazole and other therapies are ongoing, these guidelines are considered interim guidelines until new information becomes available. This document focuses on the management of patients affected by gambiense HAT and constitutes an update to the WHO therapeutic guidance issued in 2013.




Human Emerging and Re-emerging Infections


Book Description

Emerging and re-emerging pathogens pose several challenges to diagnosis, treatment, and public health surveillance, primarily because pathogen identification is a difficult and time-consuming process due to the “novel” nature of the agent. Proper identification requires a wide array of techniques, but the significance of these diagnostics is anticipated to increase with advances in newer molecular and nanobiotechnological interventions and health information technology. Human Emerging and Re-emerging Infections covers the epidemiology, pathogenesis, diagnostics, clinical features, and public health risks posed by new viral and microbial infections. The book includes detailed coverage on the molecular mechanisms of pathogenesis, development of various diagnostic tools, diagnostic assays and their limitations, key research priorities, and new technologies in infection diagnostics. Volume 1 addresses viral and parasitic infections, while volume 2 delves into bacterial and mycotic infections. Human Emerging and Re-emerging Infections is an invaluable resource for researchers in parasitologists, microbiology, Immunology, neurology and virology, as well as clinicians and students interested in understanding the current knowledge and future directions of infectious diseases.




Guidelines for the treatment of human African trypanosomiasis


Book Description

WHO has issued new guidelines for the treatment of human African trypanosomiasis (HAT), also known as sleeping sickness, a fatal disease provoked by a parasitic infection, transmitted by the bite of infected tsetse flies in sub-Saharan Africa. The recent development of a new molecule (fexinidazole) presents an opportunity to improve the therapeutic options. WHO has invested in following these developments, in commissioning independent evidence reviews, and in convening experts to develop new guidelines that reconfigure the therapeutic choices by giving new roles to this new molecule and the previously existing ones, in order to offer the best treatment possible for each type of patient. These guidelines are for the treatment of both disease forms: gambiense HAT, the slowly progressing form, caused by infection with Trypanosoma brucei gambiense, in western and central Africa; and rhodesiense HAT, the more rapidly progressive form, caused by T. b. rhodesiense, in eastern and southern Africa. They supersede the WHO interim guidelines for the treatment of gambiense human African trypanosomiasis, issued in 2019.




Progress in Human African Trypanosomiasis, Sleeping Sickness


Book Description

Human African Trypaniosomiasis (HAT) or sleeping sickness is an old disease to be now considered as reemergent. HAT is endemic in 36 sub-Saharan African countries, in areas where tsetse flies are found. The public health importance of HAT is underestimated, but the disease causes severe social disruption in many rural areas. Along the past fifteen years, numerous studies were made, and now, the mechanisms involved in the disease pathogenesis and in the characteristics of sleep-wake disruption become to be better understood. But, since 50 years, when current drugs were introduced, problems regarding HAT chemotherapy have not been solved. Nevertheless, in-depth studies about trypanosome metabolism have permitted to discover new drug targets. Written by specialists who are very experienced in their respective fields, the contributions provide an indispensable tool for practitioners and scientists.




Investing to Overcome the Global Impact of Neglected Tropical Diseases


Book Description

"The presence, or absence, of neglected tropical diseases (NTDs) can be seen as a proxy for poverty and for the success of interventions aimed at reducing poverty. Today, coverage of the public-health interventions recommended by the World Health Organization (WHO) against NTDs may be interpreted as a proxy for universal health coverage and shared prosperity - in short, a proxy for coverage against neglect. As the world's focus shifts from development to sustainable development, from poverty eradication to shared prosperity, and from disease-specific goals to universal health coverage, control of NTDs will assume an important role towards the target of achieving universal health coverage, including individual financial risk protection. Success in overcoming NTDs is a "litmus test" for universal health coverage against NTDs in endemic countries. The first WHO report on NTDs (2010) set the scene by presenting the evidence for how these interventions had produced results. The second report (2013) assessed the progress made in deploying them and detailed the obstacles to their implementation. This third report analyses for the first time the investments needed to achieve the scale up of implementation required to achieve the targets of the WHO Roadmap on NTDs and universal coverage against NTDs. INVESTING TO OVERCOME THE GLOBAL IMPACT OF NEGLECTED TROPICAL DISEASES presents an investment strategy for NTDs and analyses the specific investment case for prevention, control, elimination and eradication of 12 of the 17 NTDs. Such an analysis is justified following the adoption by the Sixty-sixth World Health Assembly in 2013 of resolution WHA6612 on neglected tropical diseases, which called for sufficient and predictable funding to achieve the Roadmap's targets and sustain control efforts. The report cautions, however, that it is wise investment and not investment alone that will yield success. The report registers progress and challenges and signals those that lie ahead. Climate change is expected to increase the spread of several vector-borne NTDs, notably dengue, transmission of which is directly influenced by temperature, rainfall, relative humidity and climate variability primarily through their effects on the vector. Investments in vector-borne diseases will avoid the potentially catastrophic expenditures associated with their control. The presence of NTDs will thereby signal an early warning system for climate-sensitive diseases. The ultimate goal is to deliver enhanced and equitable interventions to the most marginalized populations in the context of a changing public-health and investment landscape to ensure that all peoples affected by NTDs have an opportunity to lead healthier and wealthier lives."--Publisher's description.




Research Priorities for Chagas Disease Human African Trypanosomiasis and Leishmaniasis


Book Description

The Disease Reference Group on Chagas Disease Human AfricanTrypanosomiasis and Leishmaniasis (DRG3) was part of an independent thinktankof international experts established by the Special Programme for Researchand Training in Tropical Diseases (TDR) to identify key research prioritiesthrough systematic review of research evidence and input from stakeholders. These three distinct insect-borne diseases while caused by related kinetoplastidprotozoan pathogens have dissimilar geographical distributions a reflection oftheir different insect vectors and range of vector contact with humans. Thedisease.




Rickettsial Diseases


Book Description

The only available reference to comprehensively discuss the common and unusual types of rickettsiosis in over twenty years, this book will offer the reader a full review on the bacteriology, transmission, and pathophysiology of these conditions. Written from experts in the field from Europe, USA, Africa, and Asia, specialists analyze specific patho




Neglected Tropical Diseases - Sub-Saharan Africa


Book Description

This book provides an overview on the major neglected tropical diseases (NTDs) occurring in Sub-Saharan Africa, such as Leishmaniasis, Buruli Ulcer and Schistosomiasis. In well-structured chapters epidemiology and biology of these parasitic diseases will be discussed in detail. Further, diagnostics and therapeutic approaches as well as prevention strategies will be reviewed. The book will be of interest to basic researchers and clinicians engaged in infectious disease, tropical medicine, and parasitology, and a must-have for scientists specialized in the characteristics of the Sub-Saharan region.




The Trypanosomiases


Book Description

This state-of-the-art reference book includes comprehensive coverage of the biology and control of African, Asian and South American trypanosomiasis ("sleeping sickness") in man and animals. It describes recent research developments in the biology and molecular biology of trypanosomes (the protozoan parasite) and their vectors, and methods in diagnosis and control, such as trapping tsetse fly vectors. Different sections of the book are devoted to biology of trypanosomes, vector biology, epidemiology and diagnosis, pathogenesis, disease impact, chemotherapy and disease control, and vector control. The book contains contributions from leading experts from Europe, North and South America, and Africa.




Antiparasitic Treatment Recommendations


Book Description

This book primarily aims to provide a practical approach to diagnosing and treating parasitic diseases, highlighting major pitfalls in clinical management, referencing the current evidence regarding diagnosis and treatment, summarizing the pharmacological data of antiparasitic drugs, and offering an overview of differential diagnoses of certain clinical syndromes related to parasitic diseases.